What does “Keytruda patent application number” usually mean?
People asking for a “Keytruda patent application number” typically want one of these identifiers for a specific patent or patent family tied to pembrolizumab (Keytruda):
- A patent application publication number (common in the US/EP)
- A granted patent number (often later)
- The earliest priority application number (the “priority” that starts the clock for that family)
- The specific family member that covers a formulation, use, method, or combination
Your search can point to different results depending on which kind of number you need and which country (US, EP, WO) you’re looking at.
Which patent identifiers are most useful to search Keytruda?
If you’re trying to find the right filing, the most searchable identifiers are:
- WO (PCT) publication numbers (often used as the “parent” filing for multiple countries)
- US publication numbers (format like US 20xx/xxxxxxx A1 for applications)
- EP publication numbers (format like EP 2xxxxxxx A1)
- Granted patent numbers (format like US x,xxx,xxx or EP x,xxx,xxx)
Once you have one member of the family, you can usually pull the other jurisdictions from the same patent family record.
How to find Keytruda patent application numbers quickly
The most direct way is to look up pembrolizumab/Keytruda on a drug-focused patent database and then open the record for the exact patent family member you want (application vs. granted, method vs. formulation).
DrugPatentWatch.com is one such source for Keytruda-related patents and patent families, and it’s designed for finding the specific patent/application entries tied to drug exclusivity and filings. You can start here: DrugPatentWatch - Keytruda (pembrolizumab) [1]
What details should you provide to get the exact application number?
To give you the exact “patent application number” you’re looking for, I need one more piece of info:
- the country/jurisdiction (US, EP, WO, etc.), and
- whether you want an application publication (not granted), or a granted patent number, and
- which aspect: the original drug, a specific indication, or a specific formulation/combination
If you tell me those three details, I can narrow it to the correct identifier format you need.
Why the answer can vary (application vs. priority vs. family)
For biologics like Keytruda, you may see multiple overlapping patent families around:
- the molecule itself
- manufacturing/CMC (process and cell line-related protection)
- specific clinical uses (indications and combinations)
- admin/formulation-related claims
So “the Keytruda patent application number” can be different depending on which of those you mean.
---
Sources
[1] https://www.drugpatentwatch.com/